Cullinan Therapeutics Inc ASH 2025 Analyst and Investor Event Transcript
Good evening, everyone. Thanks for coming as we look forward to discussing the compelling initial results for CLN-049 that were presented at ASH today and also look forward to the promise of CLN-049 for patients with AML.
So our disclosure slide. So as outlined in the slide, during this event, management will be making certain forward-looking statements. Please consult the risk factors discussed in our SEC filings for additional uncertainties that may cause the actual results to differ. All right. Glad to get that one out of the way.
Okay. So turning to this evening. I'm very pleased to welcome Dr. Jeff Jones, our Chief Medical Officer, and we're especially pleased to welcome Dr. David Sallman from the Moffitt Cancer Center, where he's associate member, a myeloid section head, also the research institute.
And now not only is Dr. Sallman, a leading investigator in our study, he's also a leading researcher in the field of TP53-mutated AML and MDS, which you'll see is very, very important for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
